Search
Padimate O
go.drugbank.com/drugs/DB11570ApprovedIt is a structurally-related compound to [DB02362] that absorbs UV-B rays to prevent photodamage. … Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA [L2153].
Synonyms: Padimate O, Padimate-OMixtures: Kiss My Face Everyday Moisturizer SPF 15-lot, Kiss My Face SPF 18 Lip BalmSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] … [A193671] One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody with the topoisomerase I inhibitor SN-38.
Categories: Trop-2-Directed Monoclonal AntibodiesProducts: TRODELVY 200 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADET, TRODELVY®Clofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawnIt was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. … [A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: Fazim 50 mg Capsule, CLOFZIMIN® 100 MGLevosulpiride
go.drugbank.com/drugs/DB16021InvestigationalSynonyms: S-(-)-SulpirideMixtures: LEPRIT® ENZIMATICOGRAGEAS, LEPRIT® ENZIMATICOGRAGEASHyperkeratosis follicularis et parafollicularis
go.drugbank.com/conditions/DBCOND0020027Drugs: Salicylic acidSynonyms: Hyperkeratosis follicularis et parafollicularis, Keratosis follicularis et parafollicularis in cutem penetransBoceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnBoceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. … Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: VICTRELIS ® CAPSULAS 200 MG (MOLECULA PROTEGIDA)Salicylic acid
go.drugbank.com/drugs/DB00936ApprovedInvestigationalVet approvedA compound obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions.
Mixtures: Soderm 0,5 mg/g + 20 mg/g Lösung zur Anwendung auf der Haut, Actikerall 5 mg/g + 100 mg/g Lösung zur Anwendung auf der HautCategories: Non COX-2 selective NSAIDS, Cytochrome P-450 SubstratesIndacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIt was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. … Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease.
Mixtures: ULTIBRO BREEZHALER INHALATION POWDER HARD CAPSULE 110/50 MCG, ATECTURA®BREEZHALER®150/80 MCG POLVO PARA INHALACIÓN CÁPSULA DURACategories: Adrenergic beta-2 Receptor Agonists, Heterocyclic Compounds, 2-RingApis mellifera venom
go.drugbank.com/drugs/DB10955ApprovedApis mellifera venom is an extract of Apis mellifera venom. Apis mellifera venom is used in allergenic testing.
Mixtures: ALUTARD SQ Bienengift Injektionssuspension (Anfangsbehandlung) (100 SQ E/ml, 1.000 SQ E/ml, 10.000 SQ E/ml und 100.000 SQ E/ml), ALUTARD SQ Bienengift Injektionssuspension (Anfangsbehandlung) (100 SQ E/ml, 1.000 SQ E/ml, 10.000 SQ E/ml und 100.000 SQ E/ml)Products: Venomil Honey Bee Venom (120 Mcg), ALUTARD SQ Bienengift 100.000 SQ-E/ml Injektionssuspension (Fortsetzungsbehandlung)Benznidazole
go.drugbank.com/drugs/DB11989ApprovedInvestigationalBenznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. … [L939] It is the first treatment made available in the United States for Chagas disease.
Categories: Heterocyclic Compounds, 1-Ring, P-glycoprotein substratesProducts: ABALEA ®100 MG